The stock price of Sage Therapeutics Inc (NASDAQ: SAGE) has dropped by -4.73 compared to previous close of 13.94. Despite this, the company has seen a fall of -5.14% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-26 that Sage Therapeutics’ (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company’s top line.
Is It Worth Investing in Sage Therapeutics Inc (NASDAQ: SAGE) Right Now?
Additionally, the 36-month beta value for SAGE is 0.91. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 6 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for SAGE is 49.11M and currently, short sellers hold a 18.96% ratio of that float. The average trading volume of SAGE on May 02, 2024 was 1.05M shares.
SAGE’s Market Performance
SAGE’s stock has seen a -5.14% decrease for the week, with a -23.01% drop in the past month and a -48.21% fall in the past quarter. The volatility ratio for the week is 7.37%, and the volatility levels for the past 30 days are at 6.63% for Sage Therapeutics Inc. The simple moving average for the past 20 days is -10.53% for SAGE’s stock, with a -39.39% simple moving average for the past 200 days.
Analysts’ Opinion of SAGE
Many brokerage firms have already submitted their reports for SAGE stocks, with BofA Securities repeating the rating for SAGE by listing it as a “Underperform.” The predicted price for SAGE in the upcoming period, according to BofA Securities is $14 based on the research report published on April 17, 2024 of the current year 2024.
Deutsche Bank, on the other hand, stated in their research note that they expect to see SAGE reach a price target of $21. The rating they have provided for SAGE stocks is “Hold” according to the report published on December 12th, 2023.
SAGE Trading at -27.35% from the 50-Day Moving Average
After a stumble in the market that brought SAGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.86% of loss for the given period.
Volatility was left at 6.63%, however, over the last 30 days, the volatility rate increased by 7.37%, as shares sank -22.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -40.10% lower at present.
During the last 5 trading sessions, SAGE fell by -5.14%, which changed the moving average for the period of 200-days by -71.42% in comparison to the 20-day moving average, which settled at $14.65. In addition, Sage Therapeutics Inc saw -38.72% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SAGE starting from Barrett Elizabeth, who purchase 2,000 shares at the price of $18.64 back on Aug 09 ’23. After this action, Barrett Elizabeth now owns 3,000 shares of Sage Therapeutics Inc, valued at $37,279 using the latest closing price.
Barrett Elizabeth, the Director of Sage Therapeutics Inc, purchase 1,000 shares at $50.50 during a trade that took place back on May 09 ’23, which means that Barrett Elizabeth is holding 1,000 shares at $50,500 based on the most recent closing price.
Stock Fundamentals for SAGE
Current profitability levels for the company are sitting at:
- -5.95 for the present operating margin
- 0.96 for the gross margin
The net margin for Sage Therapeutics Inc stands at -5.53. The total capital return value is set at -0.77. Equity return is now at value -54.72, with -50.61 for asset returns.
Based on Sage Therapeutics Inc (SAGE), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -128.47. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -62.65.
Currently, EBITDA for the company is -511.68 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 6.9. The receivables turnover for the company is 6.45for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.22.
Conclusion
In conclusion, Sage Therapeutics Inc (SAGE) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
